SHANGHAI

上海

,

，

April 9, 2026

2026年4月9日

/PRNewswire/ -- Oricell Therapeutics Holdings Limited ('Oricell'), a global clinical-stage biotechnology company pioneering innovative cancer immunotherapies,

/PRNewswire/ -- 奥里赛尔治疗控股有限公司（“奥里赛尔”），一家全球临床阶段的生物技术公司，致力于开创创新的癌症免疫疗法，

today

今天

announced the cumulative closing of a pre-IPO financing round in excess of $110 million. The round was co-led by Vivo Capital, Beijing Medical and Health Care Industry Investment Fund, Qiming Venture Partners, and a leading global healthcare fund. The syndicate included an international sovereign wealth fund, E-Town Capital, Luxin Venture Capital, NGS Super, Elikon Investment, and Talon Capital..

宣布完成了一轮超过1.1亿美元的首次公开募股前融资。此轮融资由维梧资本、北京医疗健康投资产业基金、启明创投和一家全球领先的医疗保健基金共同领投。银团包括一家国际主权财富基金、亦庄资本、绿鑫创投、NGS Super、Elikon Investment和Talon Capital。

Proceeds will be strategically allocated to accelerate Oricell's global expansion and clinical development, while strengthening its technological capabilities and paving the way to

所得款项将被战略性地分配，以加速奥里赛尔的全球扩张和临床开发，同时加强其技术能力，并为其铺平道路。

capital market milestones

资本市场里程碑

.

。

As a frontrunner in cell therapy, OriCell is focused on engineering CAR-Ts with global clinical impact, having already secured confirmatory proof-of-concept (POC) data across multiple pipelines. By leveraging its proprietary triad: the Ori®Ab antibody screening and engineering platform, the Ori®Armoring functional enhancement platform, and the OnGo (Fast) rapid CMC manufacturing expertise, the company has built a differentiated portfolio that positions it at the vanguard of the global CAR-T race..

作为细胞治疗领域的先行者，OriCell 专注于开发具有全球临床影响力的 CAR-T 疗法，目前已在多个管线中获得了确证性的概念验证（POC）数据。通过利用其专有的三大技术平台：Ori®Ab 抗体筛选与工程平台、Ori®Armoring 功能增强平台以及 OnGo（Fast）快速 CMC 制造技术，公司构建了差异化的研发组合，使其在全球 CAR-T 竞赛中处于领先地位。

OriCell's lead asset, Ori-C101, is a GPC3-targeted autologous CAR-T therapy for advanced hepatocellular carcinoma (HCC). Having successfully navigated investigator-initiated trials (IIT) and a registrational Phase 1 study, the program is now gearing up for pivotal trials. Clinical readouts have demonstrated a best-in-class efficacy and safety profile, with data highlighted at major forums including the ASCO Annual Meeting.

OriCell的主打产品Ori-C101是一种针对GPC3的自体CAR-T疗法，用于治疗晚期肝细胞癌（HCC）。在成功完成研究者发起的试验（IIT）和注册性的1期临床试验后，该项目现在正准备进入关键性试验。临床数据显示出同类最佳的疗效和安全性，其数据已在包括ASCO年会在内的多个重要论坛上展示。

With these promising results, Ori-C101 is positioned to become the first-in-class CAR-T therapy approved globally for HCC..

基于这些令人鼓舞的结果，Ori-C101有望成为全球首个获批用于肝细胞癌（HCC）的同类首创CAR-T疗法。

Beyond its lead asset, Oricell is aggressively advancing a diverse portfolio of next-generation modalities, including secreted, rapid-production, and in vivo CAR-T programs.

除了其主要资产外，Oricell 还在积极推进多样化的下一代模式组合，包括分泌型、快速生产型和体内 CAR-T 项目。

Dr. Huanfeng Yang, Chairman and CEO of Oricell Therapeutics, stated: 'This financing is a testament to the global potential of our science and the dedication of our team. As we approach key inflection points in our clinical programs, our priority is clear: expedite the global development of our core assets and deepening our research into revolutionary technologies, including in vivo CAR-T and solid tumor CAR-T.

杨焕峰博士，奥里赛尔治疗公司的董事长兼首席执行官表示：“这次融资证明了我们的科学在全球的潜力以及我们团队的奉献精神。随着我们的临床项目接近关键的转折点，我们的优先事项很明确：加快我们核心资产的全球开发，并深化我们对革命性技术的研究，包括体内CAR-T和实体瘤CAR-T。”

We are committed to delivering transformative therapies that offer real hope to cancer patients worldwide, positioning Oricell as a dominant force in the global immunotherapy arena.'.

我们致力于提供变革性的治疗方法，为全球癌症患者带来真正的希望，使奥里细胞成为全球免疫治疗领域的重要力量。

Mr. Shan Fu, Managing Partner at Vivo Capital, commented: 'While cell therapy is undoubtedly the future of oncology, solid tumors remain the industry's toughest nut to crack. Oricell distinguishes itself not just through best-in-class clinical data for its GPC3 CAR-T, but also through a pragmatic and visionary roadmap for next-generation modalities like in vivo CAR-T.

山珊先生，Vivo Capital的管理合伙人评论道：“尽管细胞治疗无疑是肿瘤学的未来，但实体瘤仍然是业界最难攻克的难题。Oricell不仅通过其GPC3 CAR-T的一流临床数据脱颖而出，而且还通过一条务实且富有远见的下一代模式（如体内CAR-T）路线图来区分自己。”

We have high conviction in their integrated 'Platform and Pipeline' strategy and believe they are poised to set the new standard of care in the field. Vivo Capital is eager to deploy our global network to accelerate Oricell's expansion into international markets.'.

我们对其整合的“平台与渠道”战略充满信心，并相信他们必将树立行业护理新标准。Vivo Capital渴望利用我们的全球网络，加速Oricell向国际市场的扩张。

Mr. William Hu, Managing Partner at Qiming Venture Partners, stated: 'As an early investor that has stood with Oricell since the Pre-A round, we have witnessed every milestone of its journey—from technological exploration to pipeline realization, and from local innovation to global expansion. We look forward to Oricell leveraging breakthrough cell therapy solutions and stronger clinical data to define the next generation of cancer care, bringing hope to patients worldwide.'.

胡玮先生，启明创投的管理合伙人表示：“作为从Pre-A轮融资就站在Oricell身边的早期投资者，我们见证了其发展历程中的每一个里程碑——从技术探索到产品管线的实现，从本地创新到全球扩张。我们期待Oricell利用突破性的细胞治疗方案和更强大的临床数据，定义下一代癌症治疗，为全球患者带来希望。”

About Oricell Therapeutics

关于奥里赛尔治疗学

Oricell is a clinical-stage biotechnology company developing next-generation cell therapies to address unmet needs in oncology and immunology. Powered by a proprietary technology triad: Ori®Ab (antibody discovery), Ori®Armoring (T-cell enhancement), and OnGo CMC (rapid manufacturing), Oricell has advanced a diversified pipeline targeting both solid tumors and hematologic malignancies.

Oricell是一家临床阶段的生物技术公司，致力于开发下一代细胞疗法，以满足肿瘤学和免疫学中未被满足的需求。凭借专有的技术三联体：Ori®Ab（抗体发现）、Ori®Armoring（T细胞增强）和OnGo CMC（快速制造），Oricell已经推进了针对实体瘤和血液恶性肿瘤的多样化管线。

This technical prowess and global strategy are exemplified by the development of another core candidate, OriCAR-017. Supported by compelling data from IIT in China, the program paved the way into global development, rapidly securing IND approvals from both China NMPA and US FDA, along with FDA Orphan Drug Designation (ODD) and Fast Track Designation (FTD).

这一技术实力和全球战略的典型代表是另一个核心候选产品OriCAR-017的开发。在中国IIT强有力的数据支持下，该项目迅速获得了中国NMPA和美国FDA的IND批准，并取得了FDA孤儿药资格认定（ODD）和快速通道资格认定（FTD），从而迈入全球开发阶段。

OriCAR-017 has demonstrated a favorable safety profile and robust efficacy in both IIT and registrational clinical trials, with data featured at leading global conferences including 2022 ASCO, 2022 EHA, 2024 ASCO, and published in top-tier academic journals The Lancet Haematology. These milestones underscore Oricell' capabilities in regulatory strategy, clinical development, and global execution, reflecting its commitment to transforming the future of cell therapy and delivering new hope to patients worldwide.

OriCAR-017 在研究者发起的试验 (IIT) 和注册临床试验中均展示了良好的安全性和显著的疗效，其数据在2022年ASCO、2022年EHA、2024年ASCO等全球顶尖会议上发表，并刊登在顶级学术期刊《柳叶刀·血液学》上。这些里程碑彰显了OriCell在法规策略、临床开发和全球执行方面的能力，体现了公司致力于变革细胞治疗的未来并为全球患者带来新希望的承诺。

For more information, please visit: .

有关更多信息，请访问：。

www.oricell.com

www.oricell.com

.

。

Forward-Looking Statements

前瞻性声明

This press release contains 'forward-looking statements' which are not historical facts, but instead are predictions about future events based on the beliefs as well as assumptions made by and information currently available to the management of Oricell Therapeutics Holdings Limited ('the Company' or 'Oricell').

本新闻稿包含“前瞻性陈述”，这些陈述并非历史事实，而是基于奥里赛尔治疗控股有限公司（“公司”或“奥里赛尔”）管理层的信念、假设以及目前可获得的信息，对未来的事件进行的预测。

The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

“预期”、“相信”、“继续”、“可能”、“估计”、“期望”、“打算”、“或许”、“计划”、“潜在”、“预测”、“预计”、“应该”、“目标”、“将”、“会”等词语以及类似表达旨在识别前瞻性陈述，尽管并非所有前瞻性陈述都包含这些识别词语。

Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results, performance or achievements of the Company, or industry results, to differ materially from any future results, performance or achievement implied by such forward-looking statements.

此类前瞻性陈述涉及已知和未知的风险、不确定性以及其他重要因素，这些因素可能导致公司的实际结果、业绩或成就，或行业结果，与这些前瞻性陈述所暗示的任何未来结果、业绩或成就存在重大差异。

Any forward-looking statements contained in this press release speak only as of the date of this press release. The Company assumes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise..

本新闻稿中包含的任何前瞻性陈述仅截至本新闻稿发布之日。公司不承担更新任何前瞻性陈述的义务，无论是由于新信息、未来事件或其他原因。

SOURCE Oricell Therapeutics Holdings Limited

来源：奥里赛尔治疗控股有限公司

21

21

%

%

more press release views with

更多新闻发布视图与

Request a Demo

请求演示